(E/Z) -DMU2105

• Description:

  (E/Z) -DMU2105 (Compound 7k) is a potent and highly selective CYP1B1 inhibitor. (E/Z) -DMU2105 inhibits human CYP1B1 enzyme bound to yeast-derived microsomes with an IC50 value of 10 nM. (E/Z) -DMU2105 also potently inhibits CYP1B1 expressed within ‘live’ recombinant yeast and human HEK293 kidney cells with an IC50 value of 63.65 nM. (E/Z) -DMU2105 can be used for the research of cancer, glaucoma, ischemia and obesity[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315-H319

• Target:

  Cytochrome P450

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/e-z-dmu2105.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC=CN=C1)/C=C/C2=CC=C3C=CC=CC3=C2

• Molecular Formula:

  C18H13NO

• Molecular Weight:

  259.30

• Precautions:

  P264-P280-P302+P352-P305+P351+P338-P362+P364

• References & Citations:

  [1]Horley NJ, et al. Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines. Eur J Med Chem. 2017 Mar 31;129:159-174.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1031063-36-1]